The company is affirming 2026 DefenCath guidance of $150 million to $170 million, 2027 DefenCath guidance of $100 million to $125 million, and full year 2026 financial guidance of revenue of $300 ...
Joseph Todisco EVP and Chief Operating Officer — Elizabeth Masson-Hurlburt EVP and Chief Financial Officer — Susan Blum ...
CorMedix (NASDAQ:CRMD) executives said 2025 was a “transformational” year, highlighted by DefenCath reaching peak sales of “just under $260 million,” the acquisition of Melinta Therapeutics, and the ...
CorMedix (NASDAQ: CRMD) opened meaningfully down on March 5th after reporting a massive swing to profitability but ...
Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net ...
Stocktwits on MSN
Why did CRMD stock tumble over 11% today?
CorMedix’s Q4 revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio. ・Total operating expenses for Q4 rose to $48.2 million, up 181% year-on-year. ・CorMedix ...
Zacks.com on MSN
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...
CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results